MedTrace Logo

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

NCT05599789 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-02-18

No results posted yet for this study

Summary

A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.

Conditions

  • Non Small Cell Lung Cancer Metastatic

Interventions

DRUG

Pembrolizumab in Combination with Plinabulin and Docetaxel

Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.

Sponsors & Collaborators

  • BeyondSpring Pharmaceuticals Inc.

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-01-21
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599789 on ClinicalTrials.gov